Clinical Trial Update: LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating LCL161 in patients with various forms of myelofibrosis has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Polycythemia Vera
• Post-polycythemia Myelofibrosis

Drugs mentioned

• LCL161

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2023-06-06